Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by GERLIS, L. S.
Right arrow Articles by GUMPEL, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GERLIS, L. S.
Right arrow Articles by GUMPEL, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1981 British Society for Rheumatology

research-article

ISOXEPAC IN RHEUMATOID ARTHRITIS: A DOUBLE-BLIND COMPARISON WITH ASPIRIN

L. S. GERLIS and J. M. GUMPEL

Division of Rheumatology, Northwick Park Hospital and Clinical Research Centre Harrow, Middlesex HA1 3UJ

Correspondence to: Requests for reprints to Dr. J. M. Gumpel.

Nineteen patients with rheumatoid arthritis entered a double-blind cross-over study, comparing a new anti-inflammatory agent isoxepac, 200 mg three times daily, with aspirin 1.2 g three times daily. Eighteen patients completed 2–4 weeks treatment with each drug. The treatments were similar when assessed by measurement of joint pain, grip strength, morning stiffness, patients’ global assessment and overall preference. Significantly fewer adverse effects were associated with isoxepac therapy when compared with aspirin therapy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.